Cargando…
Siponimod: A Review in Secondary Progressive Multiple Sclerosis
Oral siponimod (Mayzent(®)), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varying between individual countries. In the pivotal E...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773609/ https://www.ncbi.nlm.nih.gov/pubmed/33108633 http://dx.doi.org/10.1007/s40263-020-00771-z |